Cory E. Muraco

Cory E. Muraco is the Biomolecule Workflows Manager at MilliporeSigma, the life science business of Merck KGaA. After finishing his graduate studies at Youngstown State University (Youngstown, Ohio, USA), Cory started his career at MilliporeSigma in 2013. After holding several roles in both R&D and Marketing functions, in 2022, Cory assumed his current role as the Biomolecule Workflows Manager where he is tasked with designing, developing, and executing the marketing and R&D strategies around MilliporeSigma’s bioanalytical initiative. Cory is the author of several manuscripts appearing in trade magazines and has delivered over 100 presentations at international conferences, roundtable symposia, and at various pharmaceutical and biopharmaceutical companies.

Articles by Cory E. Muraco

Equation 1.png

Biotherapeutics have become the hottest topic in pharmaceutical research over the past decade. With the increased interest in biotherapeutics, there has been a concomitant increase in new analytical methods for characterizing these large, complex molecules. This installment of “Column Watch” discusses advances in “bottom-up” analysis of monoclonal antibodies, while highlighting the role and importance column chemistry still plays in developing highly selective high-performance liquid chromatography (HPLC) methods for peptides.

Equation 11544629113889.png

Biotherapeutics have become the hottest topic in pharmaceutical research over the past decade. With the increased interest in biotherapeutics, there has been a concomitant increase in new analytical methods for characterizing these large, complex molecules. This installment of “Column Watch” discusses advances in “bottom-up” analysis of monoclonal antibodies, while highlighting the role and importance column chemistry still plays in developing highly selective high-performance liquid chromatography (HPLC) methods for peptides.

figure 1 L1541519943046.png

The 47th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2018), chaired by Norman Dovichi, was held from 29 July to 2 August in Washington, D.C., USA. This instalment of “Column Watch” covers some of the highlights observed at the symposium. In addition, trends and perspectives on future developments in HPLC noted from the conference are presented.

figure 1 L1541691782682.png

The 47th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2018), chaired by Norman Dovichi, was held from 29 July to 2 August in Washington, D.C., USA. This instalment of “Column Watch” covers some of the highlights observed at the symposium. In addition, trends and perspectives on future developments in HPLC noted from the conference are presented.

figure 1 L1508253096092.png

Separating proteins and antibodies is a unique analytical challenge because of the complexity of the analytes. Both sample heterogeneity, because of a number of chemical modifications to the analyte, and nonspecific binding to the silica surface often result in chromatographic peak broadening and tailing. This instalment of “Column Watch” focuses on several different chromatographic strategies that analytical scientists can use to resolve and quantitate various biomacromolecules, including monoclobal antibodies (mAbs) and antibody–drug conjugates (ADCs). Selected aspects of size-exclusion, hydrophobic interaction, ion-exchange, hydrophilic interaction, and reversed-phase chromatography are discussed.